Irinotecan Fresenius Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Fresenius Kabi, is a topoisomerase I inhibitor presented as an injection solution for intravenous infusion use. It is employed in the treatment of colorectal cancer, metastatic colorectal cancer, and other solid tumours in adult patients.

GNH USA supplies Irinotecan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring reliable access to essential oncology medicines.

Irinotecan is a topoisomerase I inhibitor used in oncology for the management of specific solid‑tumour cancers.

- Colorectal cancer: improves disease control when combined with fluoropyrimidine‑based chemotherapy. - Metastatic colorectal cancer: extends progression‑free survival as part of combination regimens. - Other solid tumours: provides therapeutic benefit in selected cases such as gastric or pancreatic cancer when standard options are limited.

Irinotecan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Diarrhea: can be mild to moderate and may require antidiarrheal therapy. - Neutropenia: reduction in white blood cells increasing infection risk. - Fatigue: general tiredness often experienced by patients.

Serious or Rare Side Effects: - Severe neutropenia or febrile neutropenia: may lead to life‑threatening infections. - Severe diarrhea or colitis: can result in dehydration and electrolyte imbalance. - Hepatic toxicity: elevated liver enzymes or jaundice. - Allergic reactions: including rash, bronchospasm, or anaphylaxis. - Electrolyte disturbances: such as hypokalemia or hyponatremia.

Before initiating Irinotecan therapy, several safety considerations should be observed.

- Dose adjustment: required in patients with hepatic impairment to avoid excessive exposure. - Monitoring: perform regular complete blood counts to detect neutropenia early. - Hydration: maintain adequate fluid intake to reduce the risk of severe diarrhea. - Drug interactions: avoid concurrent use of strong CYP3A4 inhibitors that may increase SN‑38 levels. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk; safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Irinotecan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase SN‑38 exposure and toxicity. - UGT1A1 inhibitors (e.g., atazanavir): can reduce SN‑38 clearance, raising risk of neutropenia and diarrhea. - Concurrent myelosuppressive agents: may exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug levels, reducing effectiveness. - Anticoagulants (e.g., warfarin): monitor INR as Irinotecan may affect coagulation parameters. - Radiation therapy: increased risk of gastrointestinal toxicity when combined.